PMO Interview with the Innovator Series: Volume 2

Peter Hirth, PhD

Video Categories: PMO Interview with the Innovator Series

The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.
January 13, 2015

BCI Affects and Survivorship

Dr Susan K. Boolbol talks about the importance of objective evidence provided by the Breast Cancer IndexSM (BCI) in treatment decision making.

January 20, 2016

Do Therapeutic Agents Affect Healthy Stem Cells?

Dr Wainberg and Dr Gerson ponder and provide opinions on whether these investigational therapies also target healthy cells.